Cellectar Biosciences announced that it has broadened its intellectual‑property portfolio with newly issued patents in Europe, Asia‑Pacific, the Middle East and the Americas. The expansion covers the company’s flagship radiotherapeutic iopofosine I‑131 and its next‑generation Auger‑emitting program CLR 125, reinforcing protection for both the platform and the individual drug candidates.
The new patents are intended to support Cellectar’s planned conditional marketing‑authorization filing with the European Medicines Agency in the third quarter of 2026. By securing additional coverage in key markets, the company aims to safeguard its competitive advantage and create a stronger foundation for future licensing or partnership opportunities. The expanded IP estate also bolsters the value of Cellectar’s broader Phospholipid Drug Conjugate (PDC) platform portfolio, which includes CLR 125, an Auger‑emitting radiopharmaceutical in development for triple‑negative breast cancer.
The patents cover the use and formulation of iopofosine I‑131 and CLR 125, providing a comprehensive shield against potential competitors and ensuring that the company retains exclusive rights to its innovative delivery technology across multiple jurisdictions.
James Caruso, president and CEO, said, “We are seeing meaningful and timely momentum across our global IP estate at a truly pivotal moment for the company. Securing these patents in major international markets reinforces the uniqueness of our technology and provides critical intellectual property fortification. Following guidance from the EMA’s Scientific Advice Working Party (SAWP) we are advancing our planned filing for conditional marketing authorization of iopofosine I 131 for Waldenström’s macroglobulinemia in Europe. This strengthened global protection is essential to our long‑term commercial strategy—and, more importantly, it supports our commitment to delivering new, desperately needed therapeutic options to patients who continue to face limited treatment choices.”
The announcement was received positively by the market, reflecting confidence in the company’s IP strategy and its potential to support a timely regulatory submission and future commercialization opportunities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.